2019年欧洲毛霉病诊疗指南解读

中国真菌学杂志　 2021, Vol. 16 　Issue (2): 116-120.

2019年欧洲毛霉病诊疗指南解读

梁官钊, 刘维达

中国医学科学院病原微生物菌(毒)种保藏中心医学真菌中心中国医学科学院北京协和医学院皮肤病研究所真菌科, 南京 210042

收稿日期:2020-08-18 发布日期:2021-04-25
通讯作者: 刘维达,E-mail:liumyco@hotmail.com E-mail:liumyco@hotmail.com
作者简介:梁官钊,男(汉族),博士,主治医师.E-mail:guanzhaoguan@126.com

The interpretation of the 2019 global guideline for the diagnosis and management of mucormycosis: ECMM and MSG ERC

LIANG Guanzhao, LIU Weida

Received:2020-08-18 Published:2021-04-25

摘要/Abstract

摘要： 毛霉菌病具有破坏性并进展迅速，须紧急干预。自2013年欧洲毛霉诊疗指南制定以来，近年又有诸多研究进展，需要进一步更新。2019年欧洲医学真菌学联合会（ECMM）与真菌病研究小组教育与研究联合会（MSG ERC）联合发布最新毛霉病全球诊疗指南，提供了有益的诊疗策略及具体信息，但临床工作更应兼顾个体差异及国情。该文对最新指南的诊疗信息进行解读，并对比旧版诊疗指南改变以启示医学同道，思考适合我国国情的治疗策略。

中图分类号:

R519.8

梁官钊, 刘维达. 2019年欧洲毛霉病诊疗指南解读[J]. 中国真菌学杂志, 2021, 16(2): 116-120.

LIANG Guanzhao, LIU Weida. The interpretation of the 2019 global guideline for the diagnosis and management of mucormycosis: ECMM and MSG ERC[J]. Chinese Journal of Mycology, 2021, 16(2): 116-120.

参考文献

[1] Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect,2014,20(Suppl 3):5-26.
[2] Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis,2019,19(12):e405-e421.
[3] 刘涵,廖勇,杨蓉娅,等. 2013欧洲毛霉病临床诊疗指南解读[J]. 实用皮肤病学杂志,2014,7(3):201-203.
[4] 王棕杨,王有为,赵薇,等. 真菌荧光染色法在甲真菌病诊断中的效率比较[J]. 实用医院临床杂志,2019,16(3):30-33.
[5] 刘晓雨,梁官钊,郭健,等. 改良荧光染色法在皮下真菌病组织病理诊断中的应用分析[J]. 中华皮肤科杂志,2019(5):319-322.
[6] 石炳毅,巨春蓉. 器官移植受者侵袭性真菌病临床诊疗技术规范(2019版)[J]. 器官移植,2019,10(3):227-236.
[7] 赵锋,乔赛,张俊丽,等. 荧光染色技术在临床少见侵袭性真菌病中的快速诊断价值[J]. 中华微生物学和免疫学杂志,2019,39(7):538-543.
[8] Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States:a retrospective study[J]. BMC Infect Dis,2016,16(1):730.
[9] Hanba C, Svider PF, Lai W, et al. An investigation of operative outcomes:Pediatric invasive fungal sinusitis[J]. Int J Pediatr Otorhinolaryngol,2017,102:142-147.
[10] Bagshaw E, Kuessner D, Posthumus J, et al. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK[J]. Future Microbiol,2017,12:515-525.
[11] Wagner L, de Hoog S, Alastruey-Izquierdo A, et al. Arevised species concept for opportunistic Mucor species reveals species-specific antifungal susceptibility profiles[J]. Antimicrob Agents Chemother,2019,63(8):e00653-19.
[12] Wei LW, Wang H, Song YG, et al. Disfiguring Mucor irregularis infection cured by amphotericin B and itraconazole:a case report and treatment experience[J]. Mycopathologia,2019,184(5):677-682.
[13] Fu M H, Liu J, Liang G Z, et al. Successful treatment of eczema-like mucormycosis in a child by combination of intravenous drip and percutaneous injection amphotericin B[J]. Mycopathologia,2019,184(2):309-313.
[14] 吕雪莲,刘维达. 毛霉与毛霉病-实验室与临床的新挑战[J]. 中国真菌学杂志,2012,7(6):321-325.
[15] Baldin C, Soliman S, Jeon HH, et al. PCR-based approach targeting mucorales-specific gene family for diagnosis of mucormycosis[J]. J Clin Microbiol,2018,56(10):e00746-18.